Inhibrx wins trade secrets trial against I-Mab; jury rejects all misappropriation claims

Inhibrx Biosciences, Inc.

Jury found in favor of Inhibrx, rejecting I-Mab's allegations of misappropriation of trade secrets.
Lawsuit filed March 1, 2022, claimed Inhibrx and CSO Brendan Eckelman improperly used I-Mab's proprietary info.
Certain matters remain before the court; Inhibrx notes potential appeals or further proceedings.
The verdict removes a significant legal overhang for Inhibrx.
Inhibrx announced the jury verdict on November 4, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.